Sagimet Biosciences updates investor presentation; no new material data disclosed

Sagimet Biosciences Inc.

Filed an updated slide presentation as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure.
Presentation titled 'Targeting Metabolic Dysfunction with Novel Therapies to Treat MASH, Acne and Cancer' dated May 2024.
No specific financial or clinical data from the presentation were provided in the filing text.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.